These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 14970366)

  • 1. Optimal management of methotrexate intoxication in a child with osteosarcoma.
    Peyriere H; Cociglio M; Margueritte G; Vallat C; Blayac JP; Hillaire-Buys D
    Ann Pharmacother; 2004 Mar; 38(3):422-7. PubMed ID: 14970366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
    Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
    Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate clearance and clinical toxicity in osteosarcoma following high-dose methotrexate therapy.
    Iqbal MP; Khursheed M; Mahboobali N
    J Pak Med Assoc; 1989 Feb; 39(2):38-42. PubMed ID: 2499702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
    Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
    Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate-doxycycline interaction.
    Tortajada-Ituren JJ; Ordovás-Baines JP; Llopis-Salvia P; Jiménez-Torres NV
    Ann Pharmacother; 1999; 33(7-8):804-8. PubMed ID: 10466909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient.
    Krämer I; Rosentreter J; Fried M; Kühn M
    J Oncol Pharm Pract; 2021 Jun; 27(4):1000-1004. PubMed ID: 32878553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potential marker of the pharmacodynamic effect of high doses of methotrexate--homocysteine].
    Strizhevskaya AM; Senzhapova ER; Dzamraev AZ; Baykova VN
    Patol Fiziol Eksp Ter; 2014; (2):40-4. PubMed ID: 25318162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate-induced oral mucositis and salivary methotrexate concentrations.
    Oliff A; Bleyer WA; Poplack DG
    Cancer Chemother Pharmacol; 1979; 2(3):225-6. PubMed ID: 313282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
    Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
    Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.